1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Empagliflozin + linagliptin
Trade Name:
Glyxambi
Manufacturer/Distributor:
Boehringer Ingelheim Canada
Classification:
Antidiabetic agent
DPPT-4 inhibitor + SGLT2 inhibitor
ATC Class:
A10BD19 - combination of oral blood glucose lowering drugs
Status:
active
Notice of Compliance (yyyy/mm/dd):
2016/12/15
Date Marketed in Canada (yyyy/mm/dd):
2016/12/15
Presentation:
Tablet: 10 mg empagliflozin + 5 mg linagliptin. DIN: 02459752
Tablet: 25 mg empagliflozin + 5 mg linagliptin. DIN: 02459760
Comments:
For use in combination with metformin as an adjunct to diet and exercise, to achieve glycemic control in adult patients with type 2 diabetes mellitus who are inadequately controlled on metformin and empagliflozin, or inadequately controlled on metformin and linagliptin.
Back to:
Drug Product Listings 
